18.03.2021 • NewsWuxiPfizer

WuXi Buys Pfizer China Plant

China’s WuXI Biologics has agreed to buy Pfizer’s biologics manufacturing facilities in Hangzhou for an undisclosed price. The transaction is expected to close in the first half of 2021. The Shanghai-based company said the acquisition will immediately boost its capacities for commercial drug substance (DS) and drug product (DP) capacities to address surging manufacturing demand.

The GMP facilities include two 2,000 liter single-use bioreactors expandable to four 2,000 liter bioreactors, as well as capacities for vial filling and pre-filled syringes.  Chris Chen, CEO of WuXi Biologics said DS and DP capacities are in urgent need now globally.

The company added that with total estimated capacity for biopharmaceutical production planned in China, Ireland, Germany, the US and Singapore exceeding 300,000 liters after 2023, it will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

The agreement with Pfizer follows purchases earlier this year of plants in Switzerland and Germany. The biologics group is also building a biomanufacturing campus in Worcester, Massachusetts, USA, which is scheduled to go into operation in 2022.

In February, WuXi STA agreed to buy Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland, its first facility in Europe. The transaction is expected to close during the second quarter.

Earlier, WuXi Biologics agreed to purchase Bayer’s biologics substance plant at Wuppertal, Germany, for €150 million. This deal is expected to close in the first half of 2021. In January 2020, the Chinese firm acquired a Bayer plant at Leverkusen, Germany.

Author: Elaine Burridge, Freelance Journalist

China’s WuXI Biologics is buying Pfizer’s biologics manufacturing...
China’s WuXI Biologics is buying Pfizer’s biologics manufacturing facilities in Hangzhou. The deal should close in H1 2021. WuXi said it will immediately boost its capacities for commercial drug substance and drug product capacities to address surging manufacturing demand. (c) WuXI Biologics

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.